An asymptomatic woman can still have chlamydia or gonorrhea, but “screen her” is not the whole board answer. Two decisions are being tested: whether screening is indicated, and which specimen can detect urogenital infection without requiring an unnecessary pelvic exam. Confusing those steps can lead either to indiscriminate screening or to a less suitable collection plan.
Decide whether screening is indicated before choosing a specimen
For sexually active women, current U.S. recommendations support annual screening for both infections before age 25. At age 25 or older, screening is recommended when risk is increased—for example, with a new partner, multiple partners, a partner with concurrent partners or an STI, inconsistent condom use outside a mutually monogamous relationship, or a previous or coexisting STI. Local prevalence and the patient’s circumstances may also inform the risk assessment.
That first step matters when a stem gives few details. “Asymptomatic” tells you this is a screening question, not that infection is absent. But if age, sexual activity, and risk history are missing, you cannot independently conclude that screening is indicated. On an exam, use what the stem establishes; in practice, ask the missing questions rather than filling in a presumed risk profile.
Guideline tables often use the term women, but screening decisions should reflect anatomy and exposure. CDC guidance extends these cervix-based recommendations to transgender men and gender-diverse people with a cervix.
If screening is indicated, choose the urogenital specimen
For routine urogenital screening in a woman, the preferred test is a nucleic acid amplification test (NAAT) on a vaginal swab. A patient can collect the vaginal swab herself in a clinical setting when the test platform allows it; clinician collection is also appropriate. Self-collection does not mean a lower-quality test, and it can avoid a speculum examination when one is not otherwise needed.
| Collection option | How to use it | Board-relevant point |
|---|---|---|
| Self-collected vaginal swab | Use a NAAT cleared or approved for the specimen and follow the collection instructions | Preferred urogenital specimen for women; a pelvic exam is not required just to collect it |
| Clinician-collected vaginal or endocervical swab | Appropriate when an examination is otherwise indicated or the patient prefers clinician collection | Do not confuse a swab with a mandatory speculum exam in every screening visit |
| Urine NAAT | A reasonable alternative when vaginal collection is declined, unavailable, or not preferred | Urine can be used, but the vaginal swab is the preferred urogenital specimen for women |
When the assay permits, one specimen can be used to test for both organisms. Check the laboratory’s accepted specimen types and collection instructions rather than assuming every platform handles every specimen in the same way. Also, do not assume a routine Pap test automatically included chlamydia and gonorrhea testing: the STI NAAT must actually be ordered using an accepted specimen.
The board-ready answer, when screening is indicated for a woman, is: order a NAAT for both chlamydia and gonorrhea using a vaginal swab; offer self-collection, with urine NAAT as an alternative.
Match additional testing to exposure, not to the word “screening”
A vaginal specimen assesses the urogenital site; it does not answer whether infection is present at the throat or rectum. Ask about oral and anal exposure in a matter-of-fact, nonjudgmental way. Based on reported exposure and shared decision-making, rectal or pharyngeal gonorrhea testing may be considered, and rectal chlamydia testing may also be considered after receptive anal exposure. Do not turn this into automatic multisite testing for every asymptomatic patient, and do not assume a negative vaginal NAAT rules out infection at another exposed site.
Culture is not the routine first choice for asymptomatic urogenital screening when NAAT is available. For suspected gonorrhea treatment failure, however, culture with antimicrobial susceptibility testing matters because NAAT does not provide susceptibility results. That is a different clinical question from routine screening.
Catch the reasoning errors that change the answer
- Starting with the test name instead of eligibility: first establish age, sexual activity, and risk; then decide whether screening is due.
- Treating no symptoms as no infection: screening targets infections that may be silent.
- Assuming a speculum exam is necessary: an accepted self-collected vaginal swab can provide the sample without one.
- Calling urine wrong—or automatically choosing it: urine is an acceptable alternative, while a vaginal swab is the preferred urogenital specimen for women.
- Assuming one site represents every site: ask about exposure and consider site-specific testing when appropriate.
A 12-minute retrieval exercise for this MCQ
Retrieval practice means closing the guidance and recalling the decision from memory before checking it—not rereading until the answer looks familiar. Try this once on a blank page:
- Minutes 0–2: Write the screening rule for sexually active women: what changes at age 25, and which partner or personal history details raise risk?
- Minutes 2–7: For each mini-stem, write one sentence on eligibility and one on specimen choice. First: an asymptomatic, sexually active 23-year-old. Second: an asymptomatic 29-year-old whose risk history is not provided. Third: an asymptomatic patient who reports receptive anal exposure.
- Minutes 7–10: Check your answers against current guidance. The first stem meets the age-based screening criterion; the second needs a risk history before eligibility can be judged; the third calls for considering exposure-site testing rather than relying on a vaginal specimen alone.
- Minutes 10–12: Close the reference again and explain aloud why urine is an acceptable alternative but the vaginal swab is preferred, and why a pelvic exam is not automatically required.
Mark the exact point you missed—eligibility, specimen, or site. Then retrieve that point from memory once more. This makes the review specific to the reasoning the question tests rather than a general reread of STI guidelines.
Practical takeaways
- Decide who needs screening before deciding what to collect.
- For women, when asymptomatic urogenital screening is indicated, choose a chlamydia/gonorrhea NAAT using a vaginal swab; offer self-collection when available.
- For women, urine is a valid alternative, not the preferred urogenital specimen.
- Ask about exposure so that additional testing, if appropriate, samples the relevant site.
